RxDoctor Payments Data

Michele Burzynski, MD

Internal Medicine · Arlington, TXNPI 1760452684

Payments from drug & device makers

$4,750in general payments, 2019–2025

Across 287 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$864
  • Pfizer$445
  • AbbVie$342
  • Lilly USA, LLC$325
  • Novo Nordisk$320
  • Takeda Pharmaceuticals U.S.A., Inc.$307
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,727100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,750 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,691
Medicare patients
142
Services billed
3,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$105,087
EliquisApixaban47$65,043
OlumiantBaricitinib11$61,702
JanuviaSitagliptin Phosphate26$40,368
MounjaroTirzepatide32$39,754
XifaxanRifaximin12$37,214
Repatha SureclickEvolocumab42$32,467
XareltoRivaroxaban19$31,160
JardianceEmpagliflozin12$19,551
Praluent PenAlirocumab18$15,230
Breo ElliptaFluticasone/Vilanterol27$10,473
Repatha SyringeEvolocumab14$7,980
Dexlansoprazole DrDexlansoprazole19$7,848
SynthroidLevothyroxine Sodium90$7,552
Spiriva HandihalerTiotropium Bromide12$6,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$320$105,08778 claims
Lilly USA, LLCOlumiant, Mounjaro$325$101,45643 claims
PfizerEliquis$445$65,04347 claims
MerckJanuvia$12$40,36826 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$76$37,21412 claims
Johnson & JohnsonXarelto$45$31,16019 claims
Boehringer IngelheimJardiance$88$19,55112 claims
AbbVieSynthroid, Linzess, Armour Thyroid$342$14,340117 claims
GSKBreo Ellipta$112$10,47327 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$307$3,48212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →